| Name | Title | Contact Details |
|---|
The Federation of American Hospitals (FAH), founded in 1966, is the national representative of investor-owned or managed community hospitals and health systems throughout the United States and one of Washington, DC`s most respected and influential health policy and advocacy organizations. Dedicated to a market-based philosophy, we provide representation and advocacy on behalf of our members to Congress, the Executive Branch, the judiciary, media, academia, accrediting organizations and the public. The Federation of American Hospitals serves its members as a clearinghouse for information about the nation`s most vital health policy issues. These include Medicare and Medicaid, the uninsured, health care quality, patient safety, health information technology, medical liability insurance reform, rural health care, long-term hospital care, inpatient psychiatric care, hospital emergency preparedness, antitrust, compliance, the health care workforce shortage, privacy and confidentiality, tax issues, and rehabilitation services, among other important issues.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Muki Baum Association is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pascal Metrics is the preeminent provider in the healthcare industry of real-time patient safety and clinical improvement services to reduce patient harm and related cost.
NarrativeDx is the artificial intelligence platform for patient experience. Our SaaS platform is the market leader in transforming hospitals` clinical outcomes by extracting data trends and gaining visibility into the patient experience. We help hospital leaders and care providers understand and improve their institution`s patient experience, drive patient referrals, increase hospital revenue, and boost hospital reputations.